West Pharma projects 2026 profit above expectations as weight loss drug demand surges
West Pharmaceutical expects higher 2026 profits driven by strong demand for obesity drug components. The firm beat quarterly estimates as its shares rose today.
Insights:
West Pharmaceutical Services, Inc. reported fourth-quarter results today, February 12, 2026, that beat market expectations and issued a 2026 adjusted earnings-per-share forecast of $7.85 to $8.20, which is above Wall Street estimates. The company attributed the stronger-than-expected outlook to robust demand for its proprietary injection components. This development is considered material to the company’s near-term earnings and revenue outlook and is expected to influence investor valuation and market reaction.
The quarterly performance was highlighted by total revenue and proprietary-product revenue that both exceeded analyst expectations. Management cited the proprietary products unit as a key driver of growth, even as the company continues to operate its contract-manufactured products segment. The strong demand for these specialized components from medical equipment makers and global pharmaceutical companies has provided a solid foundation for the upward revision in guidance.
